Literature DB >> 7492110

Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.

D Sewell1, A Barry, S Allen, P Fuchs, J McLaughlin, M Pfaller.   

Abstract

The in vitro activity of WY-49605 (SUN5555) (WY) was compared with those of cefaclor, cefixime, and amoxicillin-clavulanic acid against 2,958 consecutive clinical isolates from five medical centers and 402 respiratory pathogens from 18 other facilities. Most members of the family Enterobacteriaceae were inhibited by WY (MIC at which 50% of the isolates are inhibited [MIC50], < or = 2.0 micrograms/ml). MIC90s of > or = 8.0 micrograms/ml were observed for Enterobacter cloacae, Serratia spp., and Proteus mirabilis. WY was the most active drug against methicillin-susceptible Staphylococcus aureus (MIC90, 0.12 microgram/ml) and other coagulase-negative staphylococci (MIC90, 4.0 micrograms/ml). The four drugs were not active against nonenteric gram-negative bacilli, methicillin-resistant Staphylococcus aureus, and Staphylococcus haemolyticus. At 2.0 micrograms/ml, WY inhibited 82% of Enterococcus faecalis strains and was equal to or superior to the other drugs against streptococci, Haemophilus influenzae, and Moraxella catarrhalis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492110      PMCID: PMC162787          DOI: 10.1128/AAC.39.7.1591

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.

Authors:  T Nishino; Y Maeda; E Ohtsu; S Koizuka; T Nishihara; H Adachi; K Okamoto; M Ishiguro
Journal:  J Antibiot (Tokyo)       Date:  1989-06       Impact factor: 2.649

2.  Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.

Authors:  M Rylander; C E Nord; S R Norrby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 3.  Penems: in vitro and in vivo experiments.

Authors:  O Zak; M Lang; R Cozens; E A Konopka; H Mett; P Schneider; W Tosch; R Scartazzini
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

4.  In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic.

Authors:  M Minamimura; Y Taniyama; E Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

6.  Comparative antibacterial activity of the penem ALP 201.

Authors:  T Bergan; J da Fonseca
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

7.  Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.

Authors:  A Tsuji; H Sato; I Tamai; H Adachi; T Nishihara; M Ishiguro; N Ohnuma; T Noguchi
Journal:  Drug Metab Dispos       Date:  1990 Mar-Apr       Impact factor: 3.922

  7 in total
  1 in total

1.  Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Ian A Critchley; James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Kate Murfitt; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.